Strs Ohio lessened its position in shares of Luminex Corporation (NASDAQ:LMNX) by 25.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,900 shares of the medical instruments supplier’s stock after selling 6,200 shares during the quarter. Strs Ohio’s holdings in Luminex Corporation were worth $363,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Luminex Corporation by 52,547.0% in the 1st quarter. BlackRock Inc. now owns 5,063,064 shares of the medical instruments supplier’s stock valued at $93,008,000 after purchasing an additional 5,053,447 shares during the last quarter. Northern Trust Corp increased its holdings in Luminex Corporation by 74.7% in the 2nd quarter. Northern Trust Corp now owns 874,427 shares of the medical instruments supplier’s stock valued at $18,467,000 after purchasing an additional 373,976 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Luminex Corporation by 15.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,841,540 shares of the medical instruments supplier’s stock valued at $38,893,000 after purchasing an additional 252,299 shares during the last quarter. Vanguard Group Inc. increased its holdings in Luminex Corporation by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 3,446,060 shares of the medical instruments supplier’s stock valued at $63,304,000 after purchasing an additional 144,813 shares during the last quarter. Finally, State Street Corp increased its holdings in Luminex Corporation by 13.0% in the 1st quarter. State Street Corp now owns 1,009,789 shares of the medical instruments supplier’s stock valued at $18,548,000 after purchasing an additional 116,351 shares during the last quarter. 76.49% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Robert J. Cresci sold 19,631 shares of the business’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $18.98, for a total transaction of $372,596.38. Following the completion of the transaction, the director now owns 260,358 shares in the company, valued at $4,941,594.84. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Luminex Corporation (NASDAQ LMNX) opened at $20.91 on Friday. The company has a market cap of $947.61, a price-to-earnings ratio of 37.09, a price-to-earnings-growth ratio of 3.31 and a beta of 0.18. Luminex Corporation has a 12 month low of $17.68 and a 12 month high of $22.27.

Luminex Corporation (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.06. The business had revenue of $74.14 million during the quarter, compared to the consensus estimate of $74.38 million. Luminex Corporation had a net margin of 9.52% and a return on equity of 6.01%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.21 earnings per share. research analysts forecast that Luminex Corporation will post 0.4 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, October 13th. Investors of record on Friday, September 22nd were paid a dividend of $0.06 per share. The ex-dividend date of this dividend was Thursday, September 21st. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.15%. Luminex Corporation’s payout ratio is currently 36.36%.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/strs-ohio-has-363000-stake-in-luminex-corporation-lmnx/1695219.html.

LMNX has been the subject of several research reports. TheStreet upgraded shares of Luminex Corporation from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Zacks Investment Research upgraded shares of Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Monday, July 17th. Jefferies Group LLC reiterated a “hold” rating and issued a $21.00 target price on shares of Luminex Corporation in a report on Friday, October 20th. ValuEngine upgraded shares of Luminex Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, BidaskClub downgraded shares of Luminex Corporation from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a strong buy rating to the company’s stock. Luminex Corporation has an average rating of “Hold” and a consensus price target of $20.00.

Luminex Corporation Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.